India’s Top Drug Maker Cipla Ropes In Teva’s Tim Crew As U.S. Plans Take Shape
This article was originally published in PharmAsia News
After hiring Teva’s Frank Pieters and Novartis’ Subhanu Saxena, Cipla has now roped in Teva’s Tim Crew to play a key role in its U.S. plans. Many see it as a sustained effort to bring in higher management bandwidth.
You may also be interested in...
Teva CEO Jeremy Levin and the CSO he hired, Michael Hayden, want to re-focus the company on innovative R&D and selective generics opportunities, and that means an overhaul of the R&D organization and new priorities for business development. Levin and Hayden spoke to IN VIVO about their goals and shaping these activities following a widely anticipated investor briefing on December 11 in New York City.
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.